MétaCan
Menu
← Back to cohort

Cytokines performance during nivolumab treatment: A subgroup analysis of NIVACTOR study.

2021· article· en· W3172704995 on OpenAlexfundno aff
Nerina Denaro, Matteo Paccagnella, Danilo Galizia, Antonella Falletta, Andrea Abbona, Loretta Gammaitoni, Erika Fiorino, Lorena De Zarlo, Paolo Bossi, Dario Sangiolo, Lisa Licitra, Massimo Aglietta, Marco Merlano

Bibliographic record

VenueJournal of Clinical Oncology · 2021
Typearticle
Languageen
FieldMedicine
TopicCancer Immunotherapy and Biomarkers
Canadian institutionsnot available
FundersBristol-Myers Squibb Canada
KeywordsMedicineNivolumabInternal medicineOncologySubgroup analysisPopulationGastroenterologyImmunotherapyConfidence intervalCancer

Abstract

fetched live from OpenAlex

e18008 Background: Nivolumab is approved for 2nd line R/M SCCHN, but only ̃20% of patients will benefit. Therefore, there is an unmet need for predictive markers. Nivactor is a prospective real-life study of nivolumab in SCC-HN. We report an ancillary study on circulating cytokines in a subgroup of patients from Nivactor. Methods: We analysed changes of circulating cytokines (IL-2/4/5/6/8/10/12/13/15, CCL-2/4/22, CXCL-10, IFN-γ, TGF-β, TNF-α, VEGF) during nivolumab therapy at baseline (T0), cycle 3 (T1), cycle 7 (T2) and at disease progression (TPD). ROC analysis identifies cytokines that correlate best with PFS and OS and calculate cut-off points. Cox analysis was performed to assess HR. Hierarchical Clustering on Principal Components (HCPC) was performed to cluster pts and then compared clusters for good or poor PFS and OS. Correction for multiplicity was applied. Results: 19 pts were analysed. Using ROC analysis, we were able to identify cut-off values correlated with PFS at T0 only for IL-6 and IL-10. Similarly, we identified IL-6, IL-10, TGF-β and VEGF cut-off for OS. Then we performed Cox analysis dividing the population based on the identified cut-offs and we found that pts with IL-6 or IL-10 lower than cut off had a significant better PFS and OS (p = 0.049 and p = 0.003 for PFS, respectively; p = 0.029 and p = 0.006 for OS, respectively). TGF-β lower than cut-off correlates with better OS (p = 0.02). Interestingly, pts with all the 3 cytokines below the cut-off show the best OS. Finally, we performed a multivariate analysis using HCPC to identify 4 clusters of pts. Cluster 2 has the best PFS and OS than all other cluster considered together (p = 0.001 and p = 0.004 respectively). Patients in cluster 2 show at T0 lower IL-6/10/15 and at T1 lower IL-5/10 and higher IFN-γ compared to the others. Longitudinal analysis among the 3 time points shows that the increase of IFN-γ, IL-5 and IL-10 between T0 and T1 correlates with better PFS (p = 0.01, p = 0.03, p = 0.02, respectively); only IFN-γ and IL-5 correlates with better OS (p = 0.04; p = 0.02, respectively). Conclusions: ROC analysis can identify cytokines whose basal level may predict patients that could benefit from nivolumab treatment: low IL-6 and IL-10 positively influence both PFS and OS. Low TGF-β does not correlate with PFS but only with better OS and can be considered a pure prognostic marker. Longitudinal analysis offers information on the effect of treatment on circulating cytokines, and show that the subgroup of pts with better PFS exhibits an increase of inflammatory cytokines values.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame machine prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.

metaresearch head score (Codex)0.001
metaresearch head score (Gemma)0.001
Version: metacan-v3-hybrid-931329e0061cValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Observational · Consensus signal: Observational
GenreCandidate signal: Empirical · Consensus signal: Empirical
Teacher disagreement score0.001
Threshold uncertainty score0.007

Distilled classifier scores by category (both heads)

CategoryCodexGemma
Metaresearch0.0010.001
Meta-epidemiology (narrow)0.0010.000
Meta-epidemiology (broad)0.0010.002
Bibliometrics0.0000.000
Science and technology studies0.0000.000
Scholarly communication0.0010.000
Open science0.0000.000
Research integrity0.0000.000
Insufficient payload (model declined to judge)0.0010.000

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.110
GPT teacher head0.453
Teacher spread0.343 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designObservational
Domainnot available
GenreEmpirical

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations0
Published2021
Admission routes1
Has abstractyes

Explore more

Same venueJournal of Clinical Oncology→Same topicCancer Immunotherapy and Biomarkers→French-language works237,207→